RANI - This Recent Biologics IPO Could Be Heading Toward a Gain of 60% or More
There's a good chance that someone you know (if not you personally) has a fear of syringes or injections. An estimated 50 million Americans share that fear, and a 2019 article published in the Journal of Advanced Nursing showed that 20% to 30% of all people between the ages of 20 and 40 are afflicted by it.
For those who live with that fear, along with diseases such as arthritis, osteoporosis, Crohn's disease, and diabetes, help might be on the way. Rani Therapeutics Holdings (NASDAQ: RANI) , which specializes in orally administered biologics, is developing an encouraging first-of-its-kind solution to deliver drug treatments without injection. And its recent IPO offers investors an opportunity to get in on the action.
Image source: Getty Images
For further details see:
This Recent Biologics IPO Could Be Heading Toward a Gain of 60% or More